Vertex Pharmaceuticals' shares have soared 24% year to date despite the macroeconomic headwinds in its way. The biotech owes that in part to its dominance in the market for drugs that treat the underlying causes of cystic fibrosis (CF), an area in which Vertex is the only game in town. Revenue and earnings continue to grow for Vertex thanks to its CF franchise.
Vertex Pharmaceuticals made a bullish move on earnings amid a confirmed market rally, leading five stocks to watch this week.
Vertex Pharmaceuticals said its triple-regimen in cystic fibrosis is gaining new users abroad. VRTX stock jumped Friday.